News

Tumor Regression Discovery Gets FDA Green Light

Once considered an undruggable target, the Shokat group discovered a novel, small molecule approach to induce tumor regression. The US FDA has cleared the IND application for clinical development.

Tmunity and UCSF Announce Collaboration

Tmunity and UC San Francisco Announce Exclusive License and Research Collaboration to Advance TCR T Cell Therapies for Pediatric Cancers   – Collaboration will broaden Tmunity’s pipeline to include a glioma T cell therapy engineered to express a newly discovered T cell receptor – – Initial...

Scientists Create Speech From Brain Signals

A prosthetic voice decodes what the brain intends to say and generates (mostly) understandable speech, no muscle movement needed.

One Day There May Be a Drug to Turbocharge the Brain. Who Should Get It?

The Mysterious Hormone Called Klotho.

CRISPR-mediated Activation to Reduce Obesity

Catalyst awardees, Nadav Ahituv, PhD and Navneet Matharu, PhD, apply CRISPR-mediated activation to obesity. Here are the results:

Sana Biotechnology Launches Focusing on Engineering Cells to Create a New Class of Medicines

- Comprised of an experienced leadership team, visionary investors, and renowned scientists in cell therapy, gene therapy, and gene editing - Brings together a portfolio of potential medicines and technologies - Led by Steve Harr, M.D. as CEO and Hans Bishop as Executive Chairman

Sana Biotechnology Launches

UCSF's Sonja Schrepfer helps found startup Sana Biotechnology, as they launch with a focus on engineering cells to create a new class of medicines.

Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma

SAN DIEGO, November 6, 2018 – Fortis Therapeutics, Inc., an immuno-oncology biotech developing a novel antibody-drug conjugate (ADC) against CD46, today announced the U.S. Food and Drug Administration (FDA) has cleared two investigational new drug (IND) applications for the company’s lead candidate...

Venn Acquires Cancer Immunotherapy Antibody

Venn Therapeutics has completed an exclusive licensing deal with the University of California, San Francisco (UCSF) to advance its novel integrin αvβ8 antibody, created by a team of preeminent scientists at UCSF, led by Dr. Stephen Nishimura. Read More

Gilead Sciences and Kite to Acquire Cell Design Labs, One of UCSF Startups for $567 MM

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and its cell therapy subsidiary Kite announced that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms...